| Names | |
|---|---|
| Preferred IUPAC name
[(2R)-3-Amino-2-fluoropropyl]phosphinic acid | |
| Other names
AZD-3355
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.133.162 👁 Edit this at Wikidata |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| Properties | |
| C3H9FNO2P | |
| Molar mass | 141.082 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Lesogaberan (AZD-3355) was[1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD).[2] As a GABAB receptor agonist,[3] it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.[4]
References
[edit]- ^ AstraZeneca. "AZD3355". Archived from the original on 26 April 2012. Retrieved 30 December 2011.
- ^ Bredenoord, Albert J. (2009). "Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease". IDrugs. 12 (9): 576–584. PMID 19697277.
- ^ Alstermark; Amin, K; Dinn, SR; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors". Journal of Medicinal Chemistry. 51 (14): 4315–4320. doi:10.1021/jm701425k. PMID 18578471.
- ^ Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan". Drugs of the Future. 35 (12): 987–992. doi:10.1358/dof.2010.035.012.1540661. S2CID 258021903.
Hidden categories:
- Articles without KEGG source
- Articles with changed EBI identifier
- Articles with changed ChemSpider identifier
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Articles containing unverified chemical infoboxes
- Chembox image size set
- Articles with short description
- Short description matches Wikidata
- All stub articles